These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28366727)

  • 1. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2017 Jul; 136():24-31. PubMed ID: 28366727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface.
    Hudson RP; Dawson JE; Chong PA; Yang Z; Millen L; Thomas PJ; Brouillette CG; Forman-Kay JD
    Mol Pharmacol; 2017 Aug; 92(2):124-135. PubMed ID: 28546419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.
    Baatallah N; Elbahnsi A; Mornon JP; Chevalier B; Pranke I; Servel N; Zelli R; Décout JL; Edelman A; Sermet-Gaudelus I; Callebaut I; Hinzpeter A
    Cell Mol Life Sci; 2021 Dec; 78(23):7813-7829. PubMed ID: 34714360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of CFTR correction by type I folding correctors.
    Fiedorczuk K; Chen J
    Cell; 2022 Jan; 185(1):158-168.e11. PubMed ID: 34995514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-based corrector combination restores ΔF508-CFTR folding and function.
    Okiyoneda T; Veit G; Dekkers JF; Bagdany M; Soya N; Xu H; Roldan A; Verkman AS; Kurth M; Simon A; Hegedus T; Beekman JM; Lukacs GL
    Nat Chem Biol; 2013 Jul; 9(7):444-54. PubMed ID: 23666117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.
    Lester A; Sandman M; Herring C; Girard C; Dixon B; Ramsdell H; Reber C; Poulos J; Mitchell A; Spinney A; Henager ME; Evans CN; Turlington M; Johnson QR
    Biochemistry; 2023 Aug; 62(16):2503-2515. PubMed ID: 37437308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator.
    Bali V; Lazrak A; Guroji P; Fu L; Matalon S; Bebok Z
    FASEB J; 2016 Jan; 30(1):201-13. PubMed ID: 26336913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Measurement of Trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator to the Cell Surface and Binding to a Chemical Chaperone.
    Zhang Z; Baksh MM; Finn MG; Heidary DK; Richards CI
    Biochemistry; 2017 Jan; 56(1):240-249. PubMed ID: 28001373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Translational Folding of the First Transmembrane Domain of ABC-Transporter CFTR is Supported by Assembly with the First Cytosolic Domain.
    Kleizen B; van Willigen M; Mijnders M; Peters F; Grudniewska M; Hillenaar T; Thomas A; Kooijman L; Peters KW; Frizzell R; van der Sluijs P; Braakman I
    J Mol Biol; 2021 Jun; 433(13):166955. PubMed ID: 33771570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.